Boston's set to end Johnson & Johnson monopoly of DES (drug-eluting stent) market in US
This article was originally published in Clinica
Executive Summary
Boston Scientific moved a step closer to becoming the second entrant in the red-hot US drug-eluting stent market on November 20 2003, when its Taxus Express system easily cleared an FDA advisory committee.